These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7645440)

  • 1. The levodopa test in Parkinson's disease.
    D'Costa DF; Sheehan LJ; Phillips PA; Moore-Smith B
    Age Ageing; 1995 May; 24(3):210-2. PubMed ID: 7645440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apomorphine test in de novo Parkinson's disease.
    Bonuccelli U; Piccini P; Del Dotto P; Pavese N; D'Antonio P; Muratorio A
    Funct Neurol; 1992; 7(4):295-8. PubMed ID: 1427361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The apomorphine test in parkinsonian syndromes.
    D'Costa DF; Abbott RJ; Pye IF; Millac PA
    J Neurol Neurosurg Psychiatry; 1991 Oct; 54(10):870-2. PubMed ID: 1744640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopa-unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP?
    Imai H; Nakamura T; Kondo T; Narabayashi H
    Adv Neurol; 1993; 60():622-5. PubMed ID: 8420201
    [No Abstract]   [Full Text] [Related]  

  • 7. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G; Liss C; Reines S; Irr J; Nibbelink D
    Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of motor response to apomorphine and levodopa in Parkinson's disease.
    Kempster PA; Frankel JP; Stern GM; Lees AJ
    J Neurol Neurosurg Psychiatry; 1990 Nov; 53(11):1004-7. PubMed ID: 2283512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The apomorphine test for diagnosis of parkinsonian syndrome].
    Piccini P; Del Dotto P; Napolitano A; Pardini C; Bonuccelli U
    Riv Neurol; 1990; 60(6):221-3. PubMed ID: 2100046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.
    Weiner WJ; Factor SA; Sanchez-Ramos JR
    J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):732-5. PubMed ID: 2746265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical inquiry. Which drugs work best for early Parkinson's disease?
    Jain L; Benko R; Safranek S
    J Fam Pract; 2012 Feb; 61(2):106-8. PubMed ID: 22312616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
    Martínez-Martín P; Hernández B; Ricart J;
    Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term course in Parkinson's syndrome and cerebral polypathy (Parkinson plus).
    Fischer PA
    Adv Neurol; 1987; 45():235-8. PubMed ID: 3825695
    [No Abstract]   [Full Text] [Related]  

  • 15. Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease.
    Chase TN; Engber TM; Mouradian MM
    Adv Neurol; 1993; 60():181-5. PubMed ID: 8420133
    [No Abstract]   [Full Text] [Related]  

  • 16. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.
    Zappia M; Montesanti R; Colao R; Branca D; Nicoletti G; Aguglia U; Quattrone A
    Mov Disord; 1997 Jan; 12(1):103-6. PubMed ID: 8990062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa-induced local cerebral blood flow changes in Parkinson's disease and related disorders.
    Kobari M; Fukuuchi Y; Shinohara T; Obara K; Nogawa S
    J Neurol Sci; 1995 Feb; 128(2):212-8. PubMed ID: 7738597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clozapine withdrawal symptoms in a Parkinson's disease patient.
    Zesiewicz TA; Borra S; Hauser RA
    Mov Disord; 2002 Nov; 17(6):1365-7. PubMed ID: 12465085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

  • 20. A trial of dextromethorphan in parkinsonian patients with motor response complications.
    Verhagen Metman L; Blanchet PJ; van den Munckhof P; Del Dotto P; Natté R; Chase TN
    Mov Disord; 1998 May; 13(3):414-7. PubMed ID: 9613730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.